^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

370P - Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study

Published date:
11/28/2022
Excerpt:
We retrospectively collected data from 52 EGFR-mutant NSCLC patients with co-mutations...In the subgroup analysis of genotypes, ORR and DCR was 71.4 % and 100 % in TP53 mutation, 72.4 % and 100 % in cell cycle signaling pathway related genes, 66.7 % and 100 % in PIK3CA co-mutation, 83.3 % and 97.7 % in PD-L1 TPS 0-1, 55.6 % and 100 % in PD-L1 TPS ≥ 1...